Imaging β-amyloid using [18F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis
- 6 October 2015
- journal article
- review article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 43 (2) , 362-373
Abstract
In Alzheimer’s disease (AD), the deposition of β-amyloid (Aβ) is hypothesized to result in a series of secondary neurodegenerative processes, leading ultimately to synaptic dysfunction and neuronal loss. Since the advent of the first Aβ-specific positron emission tomography (PET) ligand, 11C-Pittsburgh compound B ([11C]PIB), several 18F ligands have been developed that circumvent the limitations of [11C]PIB tied to its short half-life. To date, three such compounds have been approved for clinical use by the US and European regulatory bodies, including [18F]AV-45 ([18F]florbetapir; Amyvid™), [18F]-BAY94-9172 ([18F]florbetaben; Neuraceq™) and [18F]3′-F-PIB ([18F]flutemetamol; Vizamyl™). The present review aims to summarize and discuss the currently available knowledge on [18F]flutemetamol PET. As the 18F analogue of [11C]PIB, [18F]flutemetamol may be of use in the differentiation of AD from related neurodegenerative disorders and may help with subject selection and measurement of target engagement in the context of clinical trials testing anti-amyloid therapeutics. We will also discuss its potential use in non-AD amyloidopathies.Keywords
This publication has 84 references indexed in Scilit:
- Development of Positron Emission Tomography β-Amyloid Plaque Imaging AgentsSeminars in Nuclear Medicine, 2012
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta2012
- Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applicationsAlzheimer's Research & Therapy, 2011
- Longitudinal assessment of Aβ and cognition in aging and Alzheimer diseaseAnnals of Neurology, 2011
- Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathologyAnnals of Neurology, 2010
- Conversion of amyloid positive and negative MCI to AD over 3 yearsNeurology, 2009
- Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils—current statusJournal of Chemical Biology, 2009
- Amyloid imaging in mild cognitive impairment subtypesAnnals of Neurology, 2009
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004